Elite Pharmaceuticals, Inc.
ELTP
$0.5475
-$0.0074-1.33%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 58.70% | 48.42% | 47.93% | 73.47% | 87.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.70% | 48.42% | 47.93% | 73.47% | 87.40% |
| Cost of Revenue | 28.18% | 45.23% | 52.46% | 83.23% | 96.35% |
| Gross Profit | 95.60% | 52.09% | 42.57% | 62.75% | 77.62% |
| SG&A Expenses | 39.41% | 26.34% | 62.82% | 60.54% | 57.64% |
| Depreciation & Amortization | 12.20% | 22.36% | 24.87% | 20.51% | 14.03% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.37% | 37.10% | 43.29% | 58.72% | 72.75% |
| Operating Income | 199.13% | 96.54% | 74.78% | 170.94% | 186.95% |
| Income Before Tax | -10,483.69% | -111.25% | -626.22% | -1,044.24% | -99.72% |
| Income Tax Expenses | 147.79% | 121.70% | 103.66% | 97.75% | -3,479.12% |
| Earnings from Continuing Operations | -155.23% | -121.46% | -215.64% | -135.85% | 345.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -155.23% | -121.46% | -215.64% | -135.85% | 345.29% |
| EBIT | 199.13% | 96.54% | 74.78% | 170.94% | 186.95% |
| EBITDA | 180.38% | 88.33% | 66.41% | 141.21% | 148.25% |
| EPS Basic | -152.33% | -120.20% | -208.50% | -132.57% | 348.84% |
| Normalized Basic EPS | 109.09% | 212.50% | -339.13% | -- | -142.31% |
| EPS Diluted | -228.07% | -133.61% | -294.12% | -171.77% | 192.31% |
| Normalized Diluted EPS | 109.09% | 212.50% | -339.13% | -- | -142.31% |
| Average Basic Shares Outstanding | 3.82% | 5.21% | 4.12% | 2.82% | 1.52% |
| Average Diluted Shares Outstanding | 2.86% | 4.60% | 4.29% | 3.48% | 2.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |